Doxepin N-Oxide Impurity
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Doxepin N-Oxide Impurity Product Information
Doxepin N-Oxide Impurity is listed under Metabolite and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Doxepin. The product is supplied by Clearsynth under CAT No. CS-O-10338.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Doxepin N-Oxide Impurity
CAS No.
22684-91-9
CAT No.
CS-O-10338
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C19H21NO2
Molecular Weight
295.38
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Doxepin N-Oxide Impurity is supplied with detailed characterization data compliant with regulatory guideline. Doxepin N-Oxide Impurity can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Doxepin.
Overview
Doxepin N-Oxide is a metabolite of Doxepin .
Synonyms
Doxepin N-Oxide Impurity
Application Notes
Doxepin N-Oxide is a metabolite of Doxepin .
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.